BioCentury | Jul 13, 2019
Product Development

Why Merck is in infectious disease for the long haul

...Merck Research Laboratories. In June, the pharma received approval for an sBLA of its Zerbaxa ceftolozane/tazobactam...
...bacteria. In a Phase III trial to treat hospital and ventilator-associated bacterial pneumonia (HABP/VABP), Zerbaxa ceftolozane/tazobactam...
...FDA), Silver Spring, Md. Yale University, New Haven, Conn. Erin McCallister, Senior Editor Relebactam/imipenem/cilastatin FDC Zerbaxa, ceftolozane/tazobactam (MK-7625A, cxa-201) Merck...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...Zerbaxa for bacterial pneumonia FDA approved an sNDA from Merck & Co. Inc. (NYSE:MRK) for Zerbaxa...
...for bacterial pneumonia FDA approved an sNDA from Merck & Co. Inc. (NYSE:MRK) for Zerbaxa ceftolozane/tazobactam...
...Editor Emgality, galcanezumab-gnlm (LY2951742) Invossa, TissueGene-C (invossa-k inj., tg-c) Vimizim, elosulfase alfa (BMN 110, bmn-110, galns) Zerbaxa, ceftolozane/tazobactam (MK-7625A, cxa-201) BioMarin...
BioCentury | Sep 14, 2018
Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

...Merck & Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III...
...Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Zerbaxa ceftolozane/tazobactam...
...days after the end of treatment Status: Phase III data Milestone: NA Brian Moy Zerbaxa, ceftolozane/tazobactam (MK-7625A, cxa-201) Astellas...
BioCentury | Oct 8, 2015
Product R&D

Medicines Co.'s double play

...Antibiotic Combination name Indication Astellas Pharma Inc. (Tokyo:4503); Merck & Co. Inc. (NYSE:MRK) Tazobactam Ceftolozane Zerbaxa...
BioCentury | Aug 3, 2015
Clinical News

Zerbaxa ceftolozane/tazobactam regulatory update

...EMA’s CHMP recommended approval of Zerbaxa ceftolozane/tazobactam to treat complicated intra-abdominal infections (cIAIs), acute pyelonephritis and...
...Inc. (Tokyo:4503), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Zerbaxa ceftolozane/tazobactam (formerly CXA-201...
BioCentury | Jul 13, 2015
Finance

Big news

...II data July; 2H15 Astellas Pharma Inc. (Tokyo:4503) / Merck & Co. Inc. (NYSE:MRK) Zerbaxa ceftolozane/tazobactam...
BioCentury | Mar 9, 2015
Regulation

Swift action for MDR bugs

...a challenge and the unmet need is high. Recently, FDA approved a new antibiotic, Zerbaxa ceftolozane/tazobactam...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...in 2002 and plasma in 2005) Cubist Pharmaceuticals Inc. (NASDAQ:CBST) (B)/Astellas Pharma Inc. (Tokyo:4503) Zerbaxa ceftolozane/tazobactam...
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...NMEs) plus two new combinations: HCV drug Viekira Pak from AbbVie Inc. and antibiotic Zerbaxa ceftolozane/tazobactam...
BioCentury | Jan 5, 2015
Finance

4Q14 Stock Wrap-up: Grow early, grow often

...to reduce the risk of transfusion-transmitted infections Cubist Pharmaceuticals Inc. (NASDAQ:CBST) (A) FDA approves Zerbaxa ceftolozane/tazobactam...
Items per page:
1 - 10 of 66